Immutep ADRs Rise on Trial Results for Non-Small Cell Lung Cancer Treatment

Dow Jones

May 15, 2025

By Kelly Cloonan

American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer.

Immutep climbed 16% to $2.11 on Thursday. The ADRs have declined 25% over the past 12 months.

The late-stage immunotherapy company said Thursday the combination of its Efti with Merck's Keytruda showed a 60.8% response rate for patients with advanced or metastatic non-squamous non-small cell lung cancer, compared to a historical control of 48%.

The combination also demonstrated a 90.2% disease control rate, the company said.

The combination involves eftilagimod alpha in combination with anti-PD-1 therapy Keytruda and doublet chemotherapy as first-line treatment.

Chief Executive Marc Voigt said the company's confidence in its efti treatment continues to rise with the latest trial data. Immutep now has data from 165 patients treated with the combination, with or without chemotherapy.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 15, 2025 11:36 ET (15:36 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535820005"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535820005\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535820005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 23:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535820005","market":"other","top_or_hot":-1,"title":"Immutep ADRs Rise on Trial Results for Non-Small Cell Lung Cancer Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer. \n</p>\n<p>\n  Immutep climbed 16% to $2.11 on Thursday. The ADRs have declined 25% over the past 12 months. \n</p>\n<p>\n  The late-stage immunotherapy company said Thursday the combination of  its Efti with Merck's Keytruda showed a 60.8% response rate for patients with advanced or metastatic non-squamous non-small cell lung cancer, compared to a historical control of 48%. \n</p>\n<p>\n  The combination also demonstrated a 90.2% disease control rate, the company said. \n</p>\n<p>\n  The combination involves eftilagimod alpha in combination with anti-PD-1 therapy Keytruda and doublet chemotherapy as first-line treatment. \n</p>\n<p>\n  Chief Executive Marc Voigt said the company's confidence in its efti treatment continues to rise with the latest trial data. Immutep now has data from 165 patients treated with the combination, with or without chemotherapy. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2025 11:36 ET (15:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep ADRs Rise on Trial Results for Non-Small Cell Lung Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep ADRs Rise on Trial Results for Non-Small Cell Lung Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-15 23:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer. \n</p>\n<p>\n  Immutep climbed 16% to $2.11 on Thursday. The ADRs have declined 25% over the past 12 months. \n</p>\n<p>\n  The late-stage immunotherapy company said Thursday the combination of  its Efti with Merck's Keytruda showed a 60.8% response rate for patients with advanced or metastatic non-squamous non-small cell lung cancer, compared to a historical control of 48%. \n</p>\n<p>\n  The combination also demonstrated a 90.2% disease control rate, the company said. \n</p>\n<p>\n  The combination involves eftilagimod alpha in combination with anti-PD-1 therapy Keytruda and doublet chemotherapy as first-line treatment. \n</p>\n<p>\n  Chief Executive Marc Voigt said the company's confidence in its efti treatment continues to rise with the latest trial data. Immutep now has data from 165 patients treated with the combination, with or without chemotherapy. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2025 11:36 ET (15:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1069347547.HKD","symbol_name":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535820005","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535820005","pubTimestamp":1747323360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer.Immutep climbed 16% to $2.11 on Thursday. The ADRs have declined 25% over the past 12 months.The late-stage immunotherapy company said Thursday the combination of  its Efti with Merck's Keytruda showed a 60.8% response rate for patients with advanced or metastatic non-squamous non-small cell lung cancer, compared to a historical control of 48%.The combination also demonstrated a 90.2% disease control rate, the company said.The combination involves eftilagimod alpha in combination with anti-PD-1 therapy Keytruda and doublet chemotherapy as first-line treatment.Chief Executive Marc Voigt said the company's confidence in its efti treatment continues to rise with the latest trial data. Immutep now has data from 165 patients treated with the combination, with or without chemotherapy.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","BK4139":"生物科技","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK7508":"医药生物股","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","SG9999002232.USD":"Allianz Global High Payout USD","LU0238689110.USD":"贝莱德环球动力股票基金","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK4559":"巴菲特持仓","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","BK4550":"红杉资本持仓","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","IMM.AU":"IMMUTEP LTD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK7067":"生物科技","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IMMP":"Immutep Limited","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"translate_title":"Immutep非小细胞肺癌治疗试验结果导致ADR上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMMP":0.9,"IMM.AU":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer. \n\n\n  Immutep climbed 16% to $2.11 on Thursday. The ADRs have declined 25% over the past 12 months. \n\n\n  The late-stage immunotherapy company said Thursday the combination of  its Efti with Merck's Keytruda showed a 60.8% response rate for patients with advanced or metastatic non-squamous non-small cell lung cancer, compared to a historical control of 48%. \n\n\n  The combination also demonstrated a 90.2% disease control rate, the company said. \n\n\n  The combination involves eftilagimod alpha in combination with anti-PD-1 therapy Keytruda and doublet chemotherapy as first-line treatment. \n\n\n  Chief Executive Marc Voigt said the company's confidence in its efti treatment continues to rise with the latest trial data. Immutep now has data from 165 patients treated with the combination, with or without chemotherapy. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 11:36 ET (15:36 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}